csg-admin-2019

October 21, 2021

Exacis Biotherapeutics Announces Strategic Partnership with CCRM for Specialty Manufacturing Services and Investment

Exacis Biotherapeutics Exacis uses proprietary mRNA-based cell engineering to develop off-the-shelf immune cell therapies for cancer treatment from induced pluripotent stem cells (iPSCs) Exacis has […]
September 10, 2021

Exacis Biotherapeutics Announces Key Additions to Company’s Scientific Advisory Board

Exacis Biotherapeutics Pamela Munster, MD, to advise on aspects of solid tumor treatment Caron Jacobson, MD, MMSc, to advise on cell therapy development and clinical […]
August 5, 2021

Aardvark Therapeutics, Inc., Completes $29M Series B Funding Led by Sorrento Therapeutics and Including Existing Investors and The Foundation for Prader-Willi Research

Funds will support three Phase 2 clinical trials of Aardvark’s lead compound to be initiated this year and advance additional products in the pipeline San […]
July 16, 2021

Richard Gabriel, B.S., M.B.A., Life Sciences Entrepreneur, Joins CSG Advisory Board; Deirdre Y. Gillespie, M.D., Steps Down After 15 Years

Adds deep experience in life sciences company creation and development including M&A. Brings expertise in chemical manufacturing including GMP and FDA regulatory compliance and submissions. […]